Nicholas Griner is a Scientific Program Manager-Cancer Genome Characterization Initiative (CGCI)
Dr. Griner received his BS in Biochemistry and Biology from the University of Washington in 2003. With an interest in cancer genomics, he completed his Ph.D. in the Molecular and Cellular Biology program at the University of Massachusetts-Amherst in 2011. His studies involved identifying genes involved in mammary tumor susceptibility using strains of mice that differed in their resistance to mammary tumor latency. After completion of his studies, he accepted a Henry M. Jackson postdoctoral fellowship at the Center for Prostate Disease Research. There he performed studies identifying downstream targets of the ERG oncoprotein, present in over 50% of prostate cancers. This work led to a first author publication titled “ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.” Following the completion of his fellowship, Dr. Griner accepted a position in the Office of Cancer Genomics at the National Cancer Institute as a Scientific Program Manager for the CGCI. There, he manages two active projects, the HIV+ Tumor Molecular Characterization Project (HTMCP) and the Burkitt Lymphoma Genome Sequencing Project (BLGSP). The goal of these projects is to sequence a large amount of cases to detect somatic changes that would delineate between different tumor subtypes. Dr. Griner has been an author of 7 high impact research articles and presented his research at multiple prestigious conferences. He continues to apply his knowledge and great interest of cancer genomics to identify molecular targets that can be exploited in the clinic for future cancer treatments.